Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C
Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C
The purpose of this study is to compare the sustained virologic response at post treatment
 Week 12 for each cohort (BMS-790052/Pegylated-interferon alfa 2a (pegIFNα-2a)/Ribavirin (RBV)
 versus placebo/PegIFNα-2a/RBV).
Inclusion Criteria:

 -  Participants chronically infected with HCV Genotype 4

 -  HCV RNA viral load of ≥ 10,000 IU/mL

 -  No previous exposure to an interferon formulation, RBV or HCV direct antiviral agent

 -  Results of a liver biopsy obtained within three years prior to enrollment to
 demonstrate the absence of cirrhosis. Participants with compensated cirrhosis are
 permitted, however, and any prior biopsy is permitted

 Exclusion Criteria:

 -  Evidence of decompensated liver disease

 -  Documented or suspected Hepatocellular carcinoma (HCC)

 -  Positive for Hepatitis B surface antigen (HBsAg) or Human immunodeficiency virus-1
 (HIV-1)/HIV-2 antibody at screening